Pfizer licenses Starna’s early-stage in vivo CAR-T programs

Pfizer has agreed to license three preclinical, in vivo CAR-T programs from China’s Starna Therapeutics, all aimed at autoimmune diseases. The programs are pre-IND and have not yet entered human trials.

The deal gives Pfizer exclusive development, manufacturing and commercialization rights outside Greater China. Pfizer will lead development in those territories and plans to make initial trial supplies at its U.S. facilities.

Starna will receive $330 million upfront and could earn up to $2.3 billion in development and commercial milestones, plus royalties on sales of any approved medicines.

Pfizer also gets rights to use Starna’s in vivo CAR-T technology in inflammation and immunology and oncology, and options tied to additional programs and potentially expanding territorial rights to Greater China.

In vivo CAR-T aims to genetically reprogram immune cells inside the body, rather than collecting and modifying cells outside the body. The approach is experimental, and the licensed programs remain at an early stage.

Sources:

Pfizer Enters into Exclusive Licensing Agreement with Starna Therapeutics for ...

Pfizer licenses CAR-T therapies from China's Starna in up to $2.6 billion deal

View PDF

Pfizer licenses CAR-T therapies from China's Starna in up to $2.6 billion deal

Pfizer Licenses Autoimmune Disease Programs From Starna In Deal Worth Upto $2.63 Bln

Pfizer Strikes $2.6 Billion Deal for Experimental Autoimmune Therapies

Pfizer pays $330 million for Starna's CAR-T programs

Pfizer Inc. Enters into Exclusive Licensing Agreement with Starna Therapeutics

Pfizer Enters into Exclusive Licensing Agreement with Starna...

Pfizer gets into in vivo CAR-T through licensing deal with Chinese biotech

Pfizer Inc. (PFE) Licenses Three Pre-IND CAR-T Programs for Autoimmune Diseases

Pfizer Announces Starna CAR-T Licensing Deal Worth Up to $2.6 Billion | TokenPost

Pfizer pays $330 million upfront for Starna's in vivo CAR-T programs in a ...

Fierce Pharma Asia—Moderna's scrapped Japanese plant; Rexulti's adcomm setback; Pfizer's option in 3SBio

Pfizer-Innovent $10.5B Deal & China Licensing Playbook